U.S. Markets closed

Raptor receives positive orphan drug opinion from EU committee

Raptor Pharmaceutical announced that it has received a positive opinion from the European Union Committee for Orphan Medicinal Products recommending orphan drug exclusivity for Procysbi gastro-resistant hard capsules for the treatment of proven nephropathic cystinosis. Final adoption of the opinions on drug approval and orphan exclusivity are expected from the European Commission in the coming months.